Adrenoleukodystrophy (ADL) – Competitive Landscape, Epidemiology Forecast, and Pipeline Analysis, 2018leads to reduction in the level of adrenocortical hormones.
Download the sample report at: www.pharmaproff.com/request-sample/1156
This reduced level in turn causes weakness, weight loss, coma, and changes in skin. Children with the cerebral form of X-linked adrenoleukodystrophy experience difficulty in reading, writing, understanding speech, and comprehending written material. Individuals with the cerebral form of X-linked adrenoleukodystrophy usually survive only a few years after symptoms begin. Symptoms of the adrenomyeloneuropathy occur between early adulthood and middle age.
Get the detailed analysis at: www.pharmaproff.com/report/adrenoleukodystrophy
Affected individuals develop progressive stiffness and weakness in their legs. This disease is very rare and has a low prevalence rate. Adrenal dysfunction may be treated with steroids (such as cortisol) if the adrenal gland is not producing enough hormones. Any specific treatment for X-linked adrenoleukodystrophy is not available. In May 2018, bluebird bio Inc.’s Lenti-D was granted breakthrough therapy designation for the treatment of patients with cerebral adrenoleukodystrophy (CALD), a rare, serious and life-threatening hereditary neurological disorder by the USFDA (Food and Drug Administration). Further, Viking Therapeutics and Orpheris Inc. are other key players in the pipeline.
Make enquiry before purchase at: www.pharmaproff.com/enquiry/1156
The report covers disease overview along with currently available diagnostic and treatment methods; detailed product profiles of pipeline assets; and segmentation of pipeline assets by company, phase of development, route of administration (RoA), mechanism of action (MoA), and molecule type.
Highlights of the report:
• In 2018, Lenti-d manufactured by bluebird bio Inc. received orphan drug status from the USFDA.
• There are approximately four drugs candidates in the ADL pipeline.
Recent advancements in ADL pipeline:
• In May, 2018 bluebird bio Inc.’s Lenti-D was granted breakthrough therapy designation for the treatment of patients with cerebral adrenoleukodystrophy (CALD), a rare, serious and life-threatening hereditary neurological disorder by the USFDA.
• In 2016, Viking Therapeutics received orphan drug designation for VK0214 from the USFDA for the Treatment of X-Linked Adrenoleukodystrophy.
• In November 2017, the USFDA granted orphan drug designation to OP-101, manufactured by Orpheris Inc., for the treatment of cerebral ADL.
Objective of the report:
• The ADL competitive landscape report plays a key role in tracking the emerging players in the market and helping the clients with their decision-making capabilities, and drive counter market strategies in order to gain competitive advantage.
• To understand the challenges, opportunities, and vulnerabilities across the research and development of ADL drugs.
• Identify the relationship between the product and use it for target finding, drug repurposing, and precision medicine.
• In licensing and out licensing strategies by identifying prospective partners with progressing projects for ADL to enhance and expand business potential and scope.
Segmentation of phases featured in the report:
• Marketed products
• Clinical stage products (Filed, Phase III, Phase II and Phase I)
• Non-clinical stage products (Pre-clinical and Discovery)
• Inactive (dormant) and discontinued products
Coverage of marketed and pipeline research activities in the report:
Comprehensive product profiles of marketed and pipeline products covering their research and development activities; regulatory milestones of marketed products; and competitive landscape of other strategic development affairs outlining drug designations, collaboration, and licensing details, mergers and acquisitions, patent information, and technology used.
Epidemiology forecast of ADL in the seven major markets (7MM):
This section of the report provides incident/prevalent cases of ADL along with further segmentation of patient pool by age, gender, and severity (depending on the availability of information) in the seven major markets (7MM) i.e. the U.S., EU5 (France, Germany, Spain, Italy, and the U.K.), and Japan.
Recent and upcoming strategic development activities and therapeutic segmentation in the report:
This part of the report covers details about the key recent and upcoming national and international conferences in the year. Also provided is the segmentation of marketed therapeutic assets by region, pipeline therapeutic assets by clinical trial region and status, attribute analysis, and launch timeline analysis of higher phase products (Filed, Phase III).
Company Profiles in the report:
The report also provides detailed profiles of key companies covering their business overview and services offered by them.
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.
Toll-free: +1-888-778-7886 (USA/Canada)
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Adrenoleukodystrophy (ADL) – Competitive Landscape, Epidemiology Forecast, and Pipeline Analysis, 2018 here
News-ID: 1715204 • Views: 165
More Releases for ADL
Anti-snoring Devices Market 2018 Global Analysis By key Players – Oscimed, Zqu …
Anti-snoring Devices Market 2018 Wiseguyreports.Com adds “Anti-snoring Devices Market –Market Demand, Growth, Opportunities, Analysis of Top Key Players and Forecast to 2025” To Its Research Database. Report Details: This report provides in depth study of “Anti-snoring Devices Market” using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization. The Anti-snoring Devices Market report also provides an in-depth survey of key players in the market which is based on the various objectives
Global CCTV Telephoto Zoom Lens Market 2017 : Tamron, CBC, Fujifilm, Ricoh and A …
A market study based on the " CCTV Telephoto Zoom Lens " across the globe, recently added to the repository of Market Research, is titled ‘Global CCTV Telephoto Zoom Lens Market 2017'. The Research report by QY Research Group is a market-oriented, technical, and commercial research analysis of the CCTV Telephoto Zoom Lens market. The analysis is completed using a wide range of secondary sources, databases and directories in order
Global Snore-ceasing Equipment Market 2017 : Oscimed, ADL Resources, Omnisleep, …
Global Snore-ceasing Equipment Market 2016-2017 A market study based on the " Snore-ceasing Equipment Market " across the globe, recently added to the repository of Market Research, is titled ‘Global Snore-ceasing Equipment Market 2017’. The research report analyses the historical as well as present performance of the worldwide Snore-ceasing Equipment industry, and makes predictions on the future status of Snore-ceasing Equipment market on the basis of this analysis. Get Free Sample Copy
Global High Temperature Insulation Materials Market 2017- ADL Insulflex Inc., Al …
The High Temperature Insulation Materials Market 2017 Research Report investigates a thorough and complete study on High Temperature Insulation Materials industry volume, market Share, market Trends, High Temperature Insulation Materials Growth aspects, wide range of applications, Utilization ratio, Supply and demand analysis, manufacturing capacity, Price durinf Forecast period from 2017 to 2022 The research report labeled Global High Temperature Insulation Materials Market 2017 presents the penetrating study of High Temperature Insulation
Gardere Partner Beverly Godbey Receives 2011 ADL Larry Schoenbrun Jurisprudence …
DALLAS – Beverly B. Godbey, a partner in the Dallas office of Gardere Wynne Sewell LLP, has been selected as the recipient of the 2011 Anti-Defamation League (ADL) Larry Schoenbrun Jurisprudence Award. A luncheon chaired by former Schoenbrun Award recipient Harriet Miers was held in Ms. Godbey’s honor on Dec. 16. The ADL's Larry Schoenbrun Jurisprudence Award is presented each year to civic-minded legal professionals who promote fair and equal justice for